Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination penicillin-class antibiotic and beta-lactamase inhibitor, effective against a broad spectrum of gram-positive, gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (empiric treatment)
## Adult Dosing
Standard adult dose is 3.375 g (piperacillin 3 g/tazobactam 0.375 g) intravenously every 6 hours or 4.5 g (piperacillin 4 g/tazobactam 0.5 g) intravenously every 8 hours. Duration of therapy varies by indication and clinical response, typically 7 to 14 days.
## Pediatric Dosing
For pediatric patients (1 month to 12 years) with appendicitis and intra-abdominal infections: Dosing is based on piperacillin weight, typically 90 mg piperacillin/11.25 mg tazobactam per kg per dose intravenously every 8 hours. Maximum dose is 3.375 g per dose. In febrile neutropenia, dosing is typically 100 mg piperacillin/12.5 mg tazobactam per kg per dose intravenously every 6 hours. Specific dosing may depend on local protocols.
## Dose Adjustments
Dose reduction and/or increased interval is required in patients with renal impairment (creatinine clearance < 20 mL/min). If CrCl is 20-40 mL/min, administer usual dose every 8 hours. If CrCl is < 20 mL/min, administer 2.25 g (piperacillin 2 g/tazobactam 0.25 g) every 8 hours or 3.375 g (piperacillin 3 g/tazobactam 0.375 g) every 12 hours. Hemodialysis patients: administer 2.25 g (piperacillin 2 g/tazobactam 0.25 g) every 8 hours, with an additional 0.75 g dose after each dialysis session.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactamase inhibitors.
* History of severe immediate reaction (e.g., anaphylaxis) to beta-lactam antibiotics.
## Adverse Effects
Common: Diarrhea, nausea, vomiting, rash, pruritus, headache, insomnia, elevated liver enzymes (AST, ALT). Serious: *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (especially with high doses or renal impairment), neutropenia, thrombocytopenia.
## Key Drug Interactions
* **Probenecid:** May decrease renal excretion of piperacillin and increase serum levels.
* **Aminoglycosides:** Concurrent use may result in inactivation of tazobactam in vitro; however, in vivo, they are often used together. Monitor for therapeutic efficacy.
* **Neuromuscular blocking agents:** Penicillins may prolong the action of neuromuscular blocking agents.
* **Warfarin:** May decrease warfarin's anticoagulant effect. Monitor INR closely.
* **Methotrexate:** Penicillins may decrease methotrexate clearance, increasing toxicity.
## Monitoring
* Renal function (creatinine clearance).
* Liver function tests.
* Complete blood count (especially in prolonged therapy for potential hematologic changes).
* Signs and symptoms of infection and response to therapy.
* Electrolytes.
## Clinical Pearls
* Administer as a continuous infusion in critically ill patients or those with severe sepsis/septic shock to maintain higher drug concentrations, especially against less susceptible organisms. Specific infusion rates depend on local protocols and patient condition.
* Ensure adequate hydration to minimize risk of crystalluria.
* For febrile neutropenia, initial doses are often higher, and duration is guided by resolution of neutropenia and clinical improvement.
* Tazobactam does not extend the spectrum of activity beyond piperacillin; it protects piperacillin from degradation by beta-lactamases.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and current clinical guidelines for complete details and to verify information before making therapeutic decisions.*
